<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have demonstrated that a natural <z:chebi fb="2" ids="28794">coumarin</z:chebi> compound esculetin (Esc) possesses <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, and anti-<z:mp ids='MP_0001845'>inflammation</z:mp> activities and rescues cultured primary neurons from <z:chebi fb="0" ids="31882">NMDA</z:chebi> toxicity </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the neuroprotective effects of Esc on <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion (I/R) injury in a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model in mice </plain></SENT>
<SENT sid="2" pm="."><plain>Esc (20 Î¼g) was administered intracerebroventricularly at 30 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We found that Esc significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and decreased neurological deficit scores after 75 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 24 h of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Post-treatment of Esc still provided neuroprotection even when Esc was administered after 4 h of reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Our data also indicated that intraperitoneal administration of Esc showed protective effects on cerebral I/R injury in a dose-dependent manner </plain></SENT>
<SENT sid="6" pm="."><plain>We further explored the protective mechanisms of Esc on cerebral I/R injury and found that Esc decreased cleaved caspase 3 level, a marker of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, our data demonstrated that Esc exerted its anti-apoptotic activity by up-regulating the expression of Bcl-2 and down-regulating the expression of Bax, two <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-related proteins </plain></SENT>
<SENT sid="8" pm="."><plain>Because of its clinical use as an <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and its safety profile, Esc may have a therapeutic potential for the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> in the future clinical trials </plain></SENT>
</text></document>